Neurocrine resumed with an Outperform at LeerinkLeerink resumed shares of Neurocrine with an Outperform rating and $67 price target. The firm says its survey of 51 physicians who treat Tardive dyskinesia and specialist checks on endometriosis support its view that both NBI-98854 and Elagolix could achieve blockbuster status.